Data / Drug companies / Atovaquone
Atovaquone: 19 companies and 23 products in the FDA NDC directory
Atovaquone is listed in the FDA National Drug Code Directory by 19 companies, with 23 products in commercial distribution. 21 of the products (91.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are suspension, and the newest product started marketing on June 14, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 19
- Products
- 23
- Generic (ANDA) products
- 21 (91.3%)
- Application numbers
- 8
- Routes
- Oral
- Brand names
- Mepron
- openFDA record search
- api.fda.gov
Companies that list atovaquone
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Atlantic Biologicals Corp. | 2 | suspension | Generic drugs (ANDA) | October 11, 2018 |
| GlaxoSmithKline LLC | 2 | suspension | New drug applications (NDA) | September 18, 1998 |
| Kesin Pharma Corporation | 2 | suspension | Generic drugs (ANDA) | February 6, 2026 |
| Pai Holdings, LLC DBA Pai Pharma | 2 | suspension | Generic drugs (ANDA) | April 4, 2025 |
| Abon Pharmaceuticals, LLC | 1 | suspension | Generic drugs (ANDA) | November 14, 2023 |
| American Health Packaging | 1 | suspension | Generic drugs (ANDA) | October 21, 2020 |
| Amneal Pharmaceuticals LLC | 1 | suspension | Generic drugs (ANDA) | February 9, 2011 |
| AvKARE | 1 | suspension | Generic drugs (ANDA) | June 14, 2026 |
| AvPAK | 1 | suspension | Generic drugs (ANDA) | October 14, 2025 |
| Bionpharma Inc. | 1 | suspension | Generic drugs (ANDA) | June 1, 2021 |
| Camber Pharmaceuticals, Inc. | 1 | suspension | Generic drugs (ANDA) | October 11, 2018 |
| Chartwell Governmental & Specialty RX, LLC. | 1 | suspension | Generic drugs (ANDA) | April 28, 2017 |
| Chartwell RX, LLC | 1 | suspension | Generic drugs (ANDA) | April 28, 2017 |
| Glenmark Pharmaceuticals Inc., USA | 1 | suspension | Generic drugs (ANDA) | December 31, 2017 |
| Golden State Medical Supply, Inc. | 1 | suspension | Generic drugs (ANDA) | March 30, 2021 |
| KVK-Tech, Inc. | 1 | suspension | Generic drugs (ANDA) | March 29, 2019 |
| Lohxa | 1 | suspension | Generic drugs (ANDA) | October 11, 2018 |
| Lupin Pharmaceuticals, Inc. | 1 | suspension | Generic drugs (ANDA) | June 1, 2021 |
| NorthStar RxLLC | 1 | suspension | Generic drugs (ANDA) | May 1, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Suspension | 23 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 21 | 91.3% |
| New drug applications (NDA) | 2 | 8.7% |
Pharmacologic classes
| Class | Products |
|---|---|
| Antimalarial | 23 |
| Antiprotozoal | 23 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.